Electromagnetic navigation bronchoscopy: A descriptive analysis
Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia
Review Article
Electromagnetic navigation bronchoscopy: A descriptive analysis
Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abstract
Electromagnetic navigation bronchoscopy (ENB) is an exciting new bronchoscopic technique that promises accurate navigation to peripheral pulmonary target lesions, using technology similar to a car global positioning system (GPS) unit. Potential uses for ENB include biopsy of peripheral lung lesions, pleural dye marking of nodules for surgical wedge resection, placement of fiducial markers for stereotactic radiotherapy, and therapeutic insertion of brachytherapy catheters into malignant tissue. This article will describe the ENB procedure, review the published literature, compare ENB to existing biopsy techniques, and outline the challenges for widespread implementation of this new technology.
Key words
Electromagnetic navigation bronchoscopy; global positioning system; surgical wedge resection; stereotactic radiotherapy; brachytherapy
J Thorac Dis 2012;4(2):173-185. DOI: 10.3978/j.issn.2072-1439.2012.03.08
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Introduction
Peripheral pulmonary lesions (PPLs) are common incidental findings (1). Their rising incidence has paralleled the increasing use of computed tomography (CT) as CT is approximately three times more sensitive than plain chest radiography (CXR) scans. Detection of PPLs will further increase should the community embrace the results from the recent National Lung Screening Trial (NLST). This landmark study of CT vs. CXR screening for lung cancer demonstrated a 20% reduction in lung cancer mortality in the CT screening arm. 39.1% of participants had at least one non-calcified nodule ≥4 mm in diameter, and 72.1% of these patients underwent further diagnostic evaluation (2). The majority of these nodules are not malignant (approximately 1% in the high-risk NLST population) and the challenge is, therefore, to find safer and more accurate ways to diagnose PPLs and avoid unnecessary surgical procedures.
The most appropriate biopsy technique for PPLs can be a challenging clinical risk-benefit decision and factors such as tumour size, location, patient co-morbidities including emphysematous changes around the PPL, respiratory function, and the pre-test probability of malignancy must be taken into account. Broadly speaking, the three general management strategies are: (I) watchful waiting with serial imaging to detect interval change, including the use of PET scans; (II) minimally invasive diagnostic procedures (bronchoscopy and trans-thoracic needle aspiration (TTNA)); and (III) surgical excision for diagnosis and definitive management.
CT-guided TTNA is a common method of obtaining tissue and whilst its pooled sensitivity for malignancy of 90% is impressive (3,4) it also has a false negative rate of 20-30% (5). Furthermore it is complicated by minor pneumothorax in approximately 25% of cases and major pneumothorax requiring a chest tube in 5% of cases (6). Identified risk factors for pneumothorax include smaller lesion size, deeper location, proximity to fissures and the presence of emphysema (7). Concomitant emphysema increases the pre-test probability of malignancy (if related to smoking), reduces the patient's tolerability for pneumothorax, and increases the time that intercostal catheter is needed for pneumothorax resolution. Rates of hemorrhage with TTNA are substantially higher than for bronchoscopic biopsy (8).
Of those PPLs that undergo diagnostic surgical excision, almost 20% are subsequently found to be benign, unnecessarily exposing significant numbers of patients to operative risks and reduced residual lung function (9,10). Futhermore, surgical resection has significant costs to the health system.
The diagnostic yield from transbronchial lung biopsy
(TBLBx) of PPLs has incrementally increased with the addition
of radiological guidance. Sampling with standard bronchoscopy
under fluoroscopic guidance is associated with an overall
sensitivity for malignancy between 14-63% but this is highly
dependent on lesion size (<2 cm=34%, >2 cm=63%), biopsy
method (forceps biopsy=57%, brush=54%, wash=43%), and
number of biopsies taken (4,11). CT guided transbronchial
biopsies are associated with diagnostic yields of between 65-73%
but concerns about radiation exposure and inefficient use of CT
scan time [in one study, an average of 4.1 scans per patients were
performed with a mean effective radiation dose of 0.55 mSv (12)]
has prevented widespread adoption of this technique (13).
The advent of endobronchial ultrasound radial probe (EBUSRP),
which provides a 360 degree ultrasound view of small
airways and surrounding tissue, has significantly enhanced
the bronchoscopic diagnostic yield for PPLs. The interface
between the low density alveolated parenchyma and the
solid tumour tissue is represented on ultrasound by a bright
line, providing confirmation that the EBUS-RP is situated
within the target lesion. With this technique Kurimoto et al.
demonstrated diagnostic yields between 69-77%, irrespective of
lesion size, and yield from lesions >3 cm was 92% (14). Paone
et al. demonstrated the superiority of EBUS RP compared to
conventional transbronchial biopsy (C-TBLBx) in a randomized
study of 221 patients (97 EBUS TBLBx vs. 124 C-TBLBx). The
sensitivity for diagnosis of malignant lesions was 78.7% in the
EBUS TBLBx group compared to 55.4% in the C-TBLBx group
(P=0.007); diagnostic yields were 69.2% and 78.4% for benign
and malignant lesions in the EBUS TBLBx compared to 44.4%
and 55.4% for benign and malignant lesions in the C-TBLBx
group respectively. There was no difference in sensitivity between
the two groups for lesions >3 cm, but sensitivity markedly
decreased in the C-TBLBx group in lesions ≤2 cm (EBUS
TBLBx=71% vs. C-TBLBx=23%, P<0.001) (15). When used
with a guide sheath (GS), EBUS RP has the additional advantage
of being able to tamponade the biopsy site, theoretically reducing
the risk of significant hemorrhage. The diagnostic yield of EBUS
is however limited by the lack of a real-time navigational system
to guide the operator from the central airways to the peripheral
target lesion.
The main advantage of using bronchoscopic techniques rather
than transthoracic biopsy is its superior safety profile. Whilst
EBUS RP can provide confirmation that the probe is located
within the target lesion, further improvements in yield will only
manifest once the bronchoscopist is able to steer the scope/
catheter through the branching bronchial tree to the target lesion
with the assistance of a navigational system. One such system is
superDimension's Electromagnetic Navigation Bronchoscopy
system (superDimension, Minneapolis, Minnesota).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Electromagnetic navigation bronchoscopy-description of technology
The superDimension Electromagnetic Navigation Bronchoscopy
(ENB) system (inReach system, superDimension Ltd,
Minneapolis, Minnesota) is a relatively new technology that
provides navigational assistance coupled with steering ability
to localize and sample PPLs. Initial human trials occurred in
2005 and over 20,000 procedures have since been performed
(16). The system consists of: iLogic virtual bronchoscopy
planning software; a "location board" which emits low frequency
electromagnetic waves; an extended working channel that is
similar in function to a guide sheath; an eight way steerable
catheter to enable selective cannulation of bronchi; and a
"locatable guide" containing sensors that allow precise tracking
of both position and orientation throughout the electromagnetic
field (Figure 1, 2).
Figure 1. SuperDimension steering catheter handle: note the black
arrows on the yellow ring of the catheter neck indicating the turning
direction of the locatable guide.
Figure 2. A: superDimension steering catheter handle; B: locatable
guide housed in blue Extended Working Channel (EWC); C: EWC
locking device screws onto the bronchoscope working channel port.
Preparation and execution of ENB procedures involves
several phases:
Planning phase
Procedural success is greatly influenced by accurate preprocedure
mapping of pathways leading to the target lesion,
and this in turn is highly dependent on the quality of CT scans
provided. CT images in Digital Imaging and Communications
In Medicine (DICOM) format must be of pre-specified slice
thickness, overlap and convolution kernel (all determined by
brand of machine) to be loaded onto the iLogic software either
from compact disk (CD) or through a network connection.
The software then reconstructs these images into a multiplanar
format.
The planning screen (Figure 5) consists of four panels,
showing axial, coronal and sagittal CT views, and either a
reconstructed three dimensional (3D) bronchial tree or virtual
endobronchial view Functions such as zoom, pan, distance
measurements, contrast, brightness and window level are
accessible through a toolbar. The operator can navigate through
the virtual endobronchial view as it would appear during
bronchoscopy and the corresponding location of the virtual "tip
of the bronchoscope" is tracked in all three CT views. Any point
on any view can be selected and the corresponding location will
be visible on the remaining views.
Figure 5. iLogic virtual bronchoscopy pre-planning screen. Note four viewports showing axial, coronal and sagittal CT views and virtual bronchoscopy
view. Green sphere represents the target lesion, the Purple line indicates mapped pathway and purple dots represent anatomical registration points.
Six to seven easily locatable anatomical "registration points"
(e.g., main and secondary carinas) are marked bilaterally for the
purposes of manual registration during the actual procedure (see
description of procedure below). The target lesion(s) is outlined
on any of the four views and a pathway pathway from trachea to
lesion is mapped by placing crosshairs over the relevant bronchus
and positioning waypoints ("breadcrumbs") along bronchi leading to the target lesion. Real time simultaneous location of
the cross-hairs in all four viewports helps to visualize and follow
paths that would otherwise appear invisible on single axial or
coronal views. Once planning is complete the plotted route can
be visualized on an animated virtual bronchoscopy view that
replicates the exact view that will be seen during the procedure.
All planning data can be saved to a removable USB drive for use
with the computer located in the bronchoscopy room.
Procedure - setting up the bronchoscopy suite and patient
Consistent bronchoscopy suite set-up is imperative as metal
objects and/or mobile communications devices within one
metre of the electromagnetic field will reduce system accuracy. The location board is placed underneath the patient's mattress
ensuring that the region of interest is encompassed within an
imaginary rectangular prism extending 50 cm above the location
board (Figure 7, 8). Three location pads are placed in a triangular
configuration on the patient's chest to enable precise tracking
of the locatable guide through the electromagnetic field. Either
general anaesthesia or conscious sedation may be used.
Figure 7. The superDimension location board is placed underneath the patient's mattress on a metal free bed, ensuring that the target lesion will be
encompassed by a rectangular prism 50 cm above the location board and the board is correctly orientated to the patient's head.
Figure 8. The Electromagnetic Navigation Bronchoscopy procedural computer stack situated in the bronchoscopy suite.
Description of procedure
After a surveillance bronchoscopy is completed to clear
secretions and exclude endobronchial lesions, the extended
working channel (EWC) and locatable guide (LG) are inserted
through the bronchoscopic working channel until approximately
8mm of the locatable guide is visible. Registration, the process
of matching the CT images to the patient's real life anatomy,
can then begin either as an automated process or manually. The
latest version of the iLogic software can register "automatically"
obviating the need to perform manual registration. LG
location and orientation data is fed back to the system at a
rate of 166 times per second while the operator performs a
balanced surveillance bronchoscopy. Registration accuracy
is measured as the Average Fiducial Target Registration Error
(AFTRE) and should be <5 mm. An AFTRE >5 mm signifies
unnacceptable divergence between the CT and patient anatomy
and will lead to reduced navigational accuracy (17); in this case
registration should be repeated to reduce the disparity. Once
enough data is collected to match CT and patient anatomy a
virtual bronchoscopy image will appear and navigation can
then proceed. If automatic registration fails, and with older
software versions, manual registration is required. For manual
registration, the operator is required to touch the LG to each of
the registration points marked during the planning phase.
Navigation
The procedure screen can display six simultaneous views chosen
by the operator (and saved as a default set up), including CT
axial, CT sagittal, CT coronal, 3D static map, 3D dynamic map,
tip view (a graphical representation of the steering wheel on the
LG handle), 3D CT view (a planar projection of the CT volume
located directly in front of the LG tip), video bronchoscope,
virtual bronchoscopy, maximum intensity projection (a pseudo
three dimensional projection of the CT volume below the LG
tip which demonstrates high intensity structures such as blood
vessels and lesions), and a local view (a planar CT image located
at and aligned with the LG tip) (Figure 6). The position of
the LG is displayed simultaneously in all viewports. Standard
functions such as zoom, pan, measurement, and screenshot are
available. The procedure screen also displays the selected target,
selected pathway, and distance from the LG tip to the target
centre. The planned pathway is represented by a ribbon, the
colour of which changes depending on the real-time location of
the LG relative to the path. Waypoints ("breadcrumbs") placed
during planning are represented by coloured spheres along the
pathway and the computer can provide navigational instructions
to any of these locations.
Figure 6. superDimension procedure screen showing 6 viewports. Clockwise from top left: axial CT view, MIP view, dynamic 3D view, tip view, local
view, sagittal CT view. The green sphere is the target lesion and the yellow ring represents the catheter handle.
The LG can be aimed in different directions by turning the
handle to one of eight preset positions, denoted by two arrows on
the handle, then pulling on the neck of the catheter (Figure 3, 4).
The degree of flex of the locatable guide is dependent on the
amount of pressure applied to the catheter neck and importantly,
the flex point is approximately 14 mm proximal to the LG tip.
Figure 3. Catheter handle and locatable guide housed in blue Extended
Working Channel - catheter in neutral position.
Figure 4. Squeezing of neck of catheter handle in the direction of the
white arrow results in deflection of LG and EWC. The direction of
deflection is controlled by turning the orange ring (black arrows) to any
one of eight pre-set positions.
The bronchoscope is wedged into the subsegement leading to
the target lesion and the EWC and LG are then slowly advanced
with the aim of keeping the selected waypoint in the centre of the
circle presented on the tip view. If the waypoint is not centred,
arrows will appear on the circle edge, indicated the direction
in which the LG handle needs to be turned before further
advancing the EWC/LG. The size of the sphere is proportional
to the distance between the planned waypoint and the LG tip.
Sampling
Once the LG tip is aligned with and in close proximity to the
target lesion the EWC is locked onto the bronchoscope, the LG is removed, and biopsy tools are then inserted through the EWC
in a fashion similar to the way a guide sheath is used during
EBUS RP. Fluoroscopy or radial probe EBUS can be used to
confirm EWC position in real time.
ENB is a complicated procedure requiring pre procedure
preparation and skills which will be unfamiliar to experienced
bronchoscopists. Although more complex than standard
bronchoscopy, procedural proficiency in ENB is achievable by
an experienced bronchoscopy team.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Narrative review of published literature
ENB is a relatively new technique. The first animal study was
performed by Becker et al. in 2003 and the same group published
the first human study in 2006 (18,16).
Effectiveness
The majority of published literature describes case series of PPLs
biopsied with ENB. The overall published diagnostic yield for
ENB alone is highly variable and ranges between 59% to 77.3%,
however this includes both peripheral and mediastinal lesions in
some papers (17,19-24) (Table 1). Although this yield is similar
to EBUS RP, the ENB papers only occasionally describe key
factors such as training and prior ENB experience, availability of
EBUS, and how ENB cases were selected.
The only randomised controlled trial of ENB was published
in 2007 by Eberhardt et al. (21). 120 patients with solitary
pulmonary nodules were randomised to one of three groups:
ENB alone, EBUS-RP alone, or combined ENB (to navigate)
and EBUS-RP (to confirmation placement). In the combined group, ENB navigation was repeated if the EBUS-RP was not
within the target lesion. The number of navigation attempts and
total procedure time were not reported. Forceps biopsy was the
only sampling method used with an average of 4.1 samples taken
per lesion. Despite a significantly higher mean lesion size in the
ENB group (28 vs. 25 vs. 24 mm, ENB vs. EBUS vs. combined
ENB-EBUS, P=0.03), diagnostic yields were 59%, 69% and 88%
respectively (P=0.02). The finding of higher diagnostic yield
with a multimodality procedure is intuitive - by exploiting the
strengths of each technique, the operator is able to navigate to the lesion with ENB then confirm the position within the target
with EBUS RP.
Factors affecting success
Most studies of C-TBLBx for PPLs show that the presence
of a "bronchus sign" (the finding of a bronchus leading
directly to a peripheral pulmonary lesion) favourably impacts
diagnostic yield. In a retrospective study of 65 patients with
PPL undergoing bronchoscopy (FOB) with forceps biopsy and
wash, Naidich found a positive bronchus sign correlated with
a diagnostic yield of 60% compared with a yield of 30% in PPL
with a negative bronchus sign (25).
In contrast, multivariate analysis from a study designed to
evaluate predictors of success for EBUS RP guided TBLBx found
that RP position relative to the lesion independently predicted
yield (within lesion vs. adjacent to lesion vs. outside of lesion=83%,
61%, 4% respectively P<0.001) but underlying disease, lesion
location, CT scan bronchus sign, operator or type of EBUS
probe did not (26).
Only one study has investigated the effect of "bronchus
sign" on ENB yield. 51 consecutive patients with pulmonary
nodules from a single centre underwent ENB. Samples were
obtained by alternating an aspirating needle with biopsy forceps
and cytological samples immediately underwent rapid onsite
cytopathology assessment (ROSE). Mean lesion size was
25 mm (15-35 mm), mean distance of 11 mm from pleura, 74%
had bronchus sign and most lesions were situated in the right
upper lobe. Of the 34 bronchoscopies which yielded a diagnosis
(67%), 30 were associated with a bronchus sign (88%). Of the
17 non diagnostic bronchoscopies, only 8 had a bronchus sign
(47%) (27). Multivariate analysis identified the presence of a
bronchus sign as the only variable conditioning ENB diagnostic
yield (P=0.005). This result may seem slightly surprising because
ENB, unlike EBUS RP, demonstrates the relationship of the LG
and EWC tip to the target lesions through real time computer
generated images, akin to being able to look through the walls of
the airways to the target lesion. By aligning the LG/EWC with
the target lesion, one could theoretically deploy an aspirating
needle through the EWC, directly into the lesion, irrespective of
the presence of a leading bronchus. This is one of the theoretical
advantages of ENB compared to EBUS RP.
Other factors conditioning ENB yield have been reported
in several case series but none has been systematically studied.
Whilst Gildea et al. and Wilson et al. found no difference in yield
based on lobar location, Eberhardt's multimodality study found
significantly lower yields from lower lobes in the ENB group
when compared to EBUS RP and combined EBUS RP/ENB
(29%, P=0.01), possibly due to exaggerated respiratory motion
of lesions close to the diaphragm (21,24,28). Most studies show
that diagnostic yield is independent of lesion size however only
small numbers have been compared and multivariate analyses
have not been performed. Several studies have incorporated
fluoroscopy and ROSE but it's effect on diagnostic yield,
procedure time, and number of samples taken remains unknown
(19,24).
Although both conscious sedation and general anaesthesia
(GA) have been used in published studies, the optimal method
has not been tested. In two of Eberhardt's studies, there were no
statistically significant differences in diagnostic yield according
to anaesthetic technique [sedation vs. GA 67% vs. 76%, P=0.28,
64% vs. 70%, P=0.57 (21,29)]. Bertoletti found that ENB
performed under an inhalational 50%/50% combination of
nitrous oxide/oxygen mixture was efficacious and well tolerated
(30). The optimal anaesthetic modality still needs to be
identified but in the meantime, anaesthetic method will likely
be determined by patient co-morbidities, lesion characteristics,
operator experience and anaesthetist availability.
The lack of innovation in biopsy tools over the last forty
years has contributed to a discrepancy between navigational
success and diagnostic yield (17,21). Samples from PPLs at
standard bronchoscopy by needle brush (a cytology brush with
a needle tip) had a higher diagnostic yield than transbronchial
needle aspirate, regular cytology brush or transbronchial forceps
biopsy (31). superDimension have since manufactured a needle
brush for use with their ENB system but no efficacy data has
been published. Eberhardt and colleagues investigated the use
of suction catheters as a biopsy technique. In this study, ENB
was used to navigate to 55 solitary pulmonary nodules and
EBUS RP was subsequently only used to assess whether or not
the lesion could be visualized ultrasonographically. 75.5% of
samples were diagnostic and catheter aspiration was positively
correlated with success rate. Interestingly, in lesions not seen
ultrasonographically, suction catheter was diagnostic in 100%
compared to only 33% with forceps biopsy (32).
Safety
The biggest advantage of ENB o TTNA is its superior safety
profile. Because the pleural is not breached with transbronchial
biopsy, pneumothorax rates are considerably lower than TTNA
and range between 0-10% (19-21,33,34). Rare cases of minor
hypoxemia and minor bleeding have been described but no
deaths have been reported in the published literature.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other potential applications
The ENB system has several other applications including
placement of fiducial markers and brachytherapy catheters,
guidance for transtracheal and transbronchial biopsy of
mediastinal lymph nodes and peribronchial masses, and
bronchoscopic pleural dye marking for localisation of lesions for surgery.
The benefits of using ENB to place fiducial markers for
stereotactic radiotherapy is becoming increasingly recognised.
Treatment for inoperable lung cancer using stereotactic radio
surgery rather than external beam radiotherapy allows delivery
of precisely targeted radiation to the tumour while minimising
dosage to adjacent tissue, but fiducial markers first have to be
accurately placed, either transthoracically, intravascularly, or
bronchoscopically, to enable tracking of the tumour. Despite the
latter being the safest method, bronchoscopically placed markers
are essentially placed "blindly" because the tumour cannot be
directly visualized. Using the navigational ability of ENB may
improve placement accuracy. A case series of placement of
fiducial markers using ENB assisted navigation showed accurate
localization in 8 of 9 cases and a 90% retention rate one week
later (35). In a separate study, 234 markers were successfully
placed in 52 of 60 patients. At the time of Cyberknife planning,
215/217 (99%) of the coil-spring fiducials were still in place
compared to only 8/17 (58%) of linear fiducial markers.
Pneumothorax rate was 5.8% (36).
Several abstracts have described the safe and efficient use
of ENB to place brachytherapy catheters into inoperable lung
cancers. Previously this treatment was limited to endobronchial
disease as catheters were placed under direct vision but now,
with the navigational capabilities of ENB, the catheters can be
accurately placed into lesions outside the bronchoscopic field of
view (37,38).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Challenges for clinical implementation
Whilst the theory behind ENB remains sound, several challenges
still need to be addressed to enable the technology to gain
widespread acceptance and dissemination.
Learning curve
ENB is a complex and lengthy procedure that involves a well
functioning team operating numerous pieces of equipment
and software. The ENB procedure screen provides so much
information that a conscious effort is needed to focus only on
those viewports providing data relevant to the current stage of
the procedure. In addition, the operator needs to manipulate the
navigation device whilst ensuring the bronchoscope position
does not change as the EWC is advanced. Whilst case planning
can be easily practiced using superDimension's LungQuest
software, procedural simulation models are not yet widely
available and access to the procedure screen is only possible
when an LG is connected to the system. The upshot is that the
learning curve is steep as procedural practice can only be gained
during real life cases and the cost of consumables may limit the
frequency of procedures.
The extent of the learning curve for ENB is not known.
Cicenia et al. (abstract only) studied the diagnostic yield of
48 ENB procedures in 43 patients. Consecutive patients were
placed into three groups (A, B, C) based on the chronological
time they had their procedure. Both PPLs and mediastinal
lesions were targeted with an average target size of 23+/–12 mm.
The diagnostic yield of groups A, B and C was 58.8%, 87.5%,
and 93.3% respectively, leading the authors to conclude that
approximately 15 procedures are needed before obtaining
procedural proficiency (39). Makris, on the other hand,
found no difference in diagnostic yield between first 13/last
13 procedures and first 7/last 7 procedures in two different
operators who performed 26 and 14 consecutive procedures
respectively (33). In our experience the learning curve for ENB
is real and can be steep. We feel that new operators would benefit
from both hands-on training and procedural simulation.
Cost
As with most emerging technologies, the cost of ENB is high and
its use is limited to specialized centres. The cost-effectiveness of
ENB has yet to be published although two health technology
assessments have been undertaken. The Blue Cross of Idaho
has performed a series of systematic reviews on its utility and
have concluded that currently there is insufficient evidence to
determine the risks and benefits of ENB when compared to
standard approaches to diagnose peripheral lesion (40). The data
are also insufficient to identify which patients might benefit from
ENB. A policy statement from AETNA, an American health
insurance company, stated that "Even though the technologies
are very attractive and pilot data are extremely encouraging,
more studies establishing selection criteria and best utility are
needed" (41).
Planning CT scan issues
The success of ENB is to a large extent dependent on the quality
of the pre-procedure CT scan. Factors such as poor inspiratory
effort or motion artifact result in suboptimal airway visualization,
potentially concealing otherwise appropriate pathways and
resulting in lower diagnostic yields. The superDimension ENB
system demands very specific CT parameters (slice thickness,
slice interval, slice overlap, convolution kernel) in order to
create a three dimensional bronchial tree for optimal navigation.
Typically, however, a patient is referred to a specialist clinic only
after their general practitioner has ordered a CT scan, usually
with parameters that are incompatible with the iLogic software.
Furthermore, most radiology practices do not store the raw CT
data for more than a week, making iLogic compatible image
reconstruction impossible. In these cases, for ENB to be used,
the patient would need to undergo a repeat CT scan with the resultant additional radiation exposure. To avoid this duplication,
it is essential that radiologists and general practitioners are aware
that ENB technology is available so they can store and retrieve
the raw DICOM data to reconstruct iLogic compatible CT
scans.
Areas for research
The first animal trials of ENB were performed in 2003 yet few
randomised controlled trials have been performed, leaving
uncertainty about the place of ENB in the diagnostic algorithm
for PPLs. Pressing issues include when to choose ENB over
TTNA for diagnosing PPLs and whether ENB is useful after
failed EBUS-RP. Although multimodality procedures are
associated with higher diagnostic yields, the cost of ENB makes
it unlikely that combined EBUS/ENB procedures will become
routine for every PPL. It will also be important to compare ENB
with other ancillary techniques such as virtual bronchoscopy
(VB) and ultra thin bronchoscopy. Comparative studies are
needed to assess the role of ENB in the placement of fiducial
markers for stereotactic radiotherapy, and evaluate newer
sampling tools such as the needle brush. Predictors of diagnostic
yield, aside from the "bronchus sign", also need to be delineated
to optimize patient selection, improve diagnostic yield and
minimise complications.
Refinement of ENB hardware and software is constantly
occurring. Most of the published research to date was performed
using older versions of the iLogic software which required
manual registration. The most recent software version defaults to
automatic registration whereby the operator performs a balanced
survey of the bilateral bronchial tree rather than touching
several pre-defined points to align the CT images with real time
anatomy. The accuracy of this "automatic registration" algorithm
has never been studied. Similarly if new steering mechanisms
or locatable guides become available, their safety and efficacy
will need to be restudied which may in turn hinder widespread
adoption.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EDoes enb add value to our current guided bronchoscopic biopsy techniques?
Direct comparisons between guided bronchoscopic techniques
and TTNA are difficult due to variation in definition of PPLs,
lesion location, methods of case selection, and biopsy methods.
Other factors that need to be considered when selecting the
appropriate diagnostic modality include type of equipment
available, local expertise and patient characteristics.
Several studies have attempted to compare the various guided
bronchoscopic techniques. In a randomized controlled trial of
EBUS RP with guide sheath (GS) vs. CT TTNA, no significant
overall difference in diagnostic yield was observed but CT TTNA
had a superior yield in lesions less than 2 cm. Pneumothorax
rate was higher with CT TTNA and patient satisfaction favoured
EBUS RP (42). In Japan, The V-NINJA group randomized
peripheral lesions ≤3 cm to EBUS RP with GS with or without
navigational assistance from VB. The diagnostic yield was
significantly higher in the VB group (80.8% vs. 67.4% P=0.032),
driven primarily by successful diagnoses in lesions ≤2 cm. Total
examination time and time to initial biopsy were both shorter
in the VB group (43). A meta-analysis and systematic review
of EBUS RP for diagnosis of peripheral pulmonary lesions
that included 16 studies with 1,420 patients found an overall
sensitivity of 0.73 (95% CI 0.70-0.76) for detection of lung
cancer. There was significant inter-study heterogeneity most
likely due to prevalence of malignancy, lesion size, and reference
standard used (44). Wang Memoli et al. recently published a
meta-analysis of guided bronchoscopy including studies of VB,
ENB, GS, ultra thin bronchoscopy (UTB) and EBUS RP (45).
All methods were safe with an adverse event rate of only 1.6%
(mostly pneumothorax). Pooled diagnostic yield was 70%. VB,
EBUS RP and GS had higher yields than average (VB=72%,
EBUS RP=71.1%, GS=73.2%) whereas ENB had the lowest
weighted diagnostic yield (67%).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conclusions
Electromagnetic nav igation bronchoscopy is gaining
increasing acceptance as a diagnostic modality, particularly
in North America and Europe. Currently, high level evidence
underpinning the technique is limited and its position in the
diagnostic algorithm of PPLs remains unclear. This was reflected
in the 2011 British Thoracic Society bronchoscopy guidelines
and the 2007 ACCP lung cancer guidelines (4,46). The cost of
ENB is also a major drawback (46). On the other hand, it is a
relatively new technology and the evidence base will no doubt
mature over time. Modifications in hardware and software
continue with the hope of improved diagnostic yield and user
friendliness however each innovation demands independent
evaluation. Ultimately, high level research directly comparing
diagnostic yield of ENB to CT TTNA in patients who have failed
EBUS RP, comparison of ENB against other techniques such as
ultra thin bronchoscopy and virtual bronchoscopy, are required
as well as studies examining predictors of success in order to
clarify utility and place in diagnostic algorithm.
Despite the challenges outlined above together with high
cost and learning curve, the navigational ability of ENB offers
the potential for wider clinical applicability, both diagnostic and
therapeutic, than is possible with conventional bronchoscopy.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acknowledgements
We sincerely thank the patients and staff of The Prince Charles
Hospital for their participation in our research studies. Our work
is supported by NHMRC project grants, NHMRC Practitioner
Fellowship (KF), NHMRC Career Development Fellowship
(IY), NHMRC Medical Category 1 Biomedical Postgraduate
Research Scholarship (HM), Cancer Council Queensland Senior
Research Fellowship (KF), Cancer Council Queensland, Cancer
Australia, Office of Health and Medical Research (OHMR),
Australian Post Graduate Award Scholarship (SL) and The
Prince Charles Hospital Foundation.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
Cite this article as: Leong S, Ju H, Marshall H, Bowman R, Yang I, Ree
AM, Saxon C, Fong KM. Electromagnetic navigation bronchoscopy: A
descriptive analysis. J Thorac Dis 2012;4(2):173-185. doi: 10.3978/
j.issn.2072-1439.2012.03.08
|